en.unionpedia.org

Alirocumab, the Glossary

Index Alirocumab

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by diet and statin treatment.[1]

Table of Contents

  1. 46 relations: Amgen, Apheresis, Atherosclerosis, Biological target, BioMarin Pharmaceutical, Biopharmaceutical, Cardiovascular disease, Chinese hamster ovary cell, Clinical trial, CVS Caremark, Disulfide, Drug discovery, European Medicines Agency, Express Scripts, Familial hypercholesterolemia, Fetus, Food and Drug Administration, Forbes, Health Canada, Hypercholesterolemia, Immunoglobulin heavy chain, Immunoglobulin light chain, Indication (medicine), Industrial fermentation, Injection site reaction, Injunction, International nonproprietary name, Investigational New Drug, Kidney dialysis, LDL receptor, Low-density lipoprotein, Medication, Monoclonal antibody, Patent infringement under United States law, PCSK9, Pharmacy benefit management, Placebo, Priority review, Proteolysis, Recombinant DNA, Regeneron Pharmaceuticals, Sanofi, Statin, Subcutaneous administration, The New England Journal of Medicine, Therapy.

  2. PCSK9 inhibitors

Amgen

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California.

See Alirocumab and Amgen

Apheresis

Apheresis (ἀφαίρεσις (aphairesis, "a taking away")) is a medical technology in which the blood of a person is passed through an apparatus that separates out one particular constituent and returns the remainder to the circulation.

See Alirocumab and Apheresis

Atherosclerosis

Atherosclerosis is a pattern of the disease arteriosclerosis, characterized by development of abnormalities called lesions in walls of arteries.

See Alirocumab and Atherosclerosis

Biological target

A biological target is anything within a living organism to which some other entity (like an endogenous ligand or a drug) is directed and/or binds, resulting in a change in its behavior or function.

See Alirocumab and Biological target

BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California.

See Alirocumab and BioMarin Pharmaceutical

Biopharmaceutical

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources.

See Alirocumab and Biopharmaceutical

Cardiovascular disease

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels.

See Alirocumab and Cardiovascular disease

Chinese hamster ovary cell

Chinese hamster ovary (CHO) cells are a family of immortalized cell lines derived from epithelial cells of the ovary of the Chinese hamster, often used in biological and medical research and commercially in the production of recombinant therapeutic proteins.

See Alirocumab and Chinese hamster ovary cell

Clinical trial

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.

See Alirocumab and Clinical trial

CVS Caremark (formerly Caremark Rx) (stylized as, previously CVS/caremark) is the pharmacy benefit management subsidiary of CVS Health, headquartered in Woonsocket, Rhode Island.

See Alirocumab and CVS Caremark

Disulfide

In chemistry, a disulfide (or disulphide in British English) is a compound containing a functional group or the anion.

See Alirocumab and Disulfide

Drug discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.

See Alirocumab and Drug discovery

European Medicines Agency

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products.

See Alirocumab and European Medicines Agency

Express Scripts

Express Scripts Holding Company is a pharmacy benefit management (PBM) organization.

See Alirocumab and Express Scripts

Familial hypercholesterolemia

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein cholesterol (LDL cholesterol), in the blood and early cardiovascular diseases.

See Alirocumab and Familial hypercholesterolemia

Fetus

A fetus or foetus (fetuses, foetuses, rarely feti or foeti) is the unborn offspring that develops from a mammal embryo.

See Alirocumab and Fetus

Food and Drug Administration

The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services.

See Alirocumab and Food and Drug Administration

Forbes

Forbes is an American business magazine founded by B. C. Forbes in 1917 and owned by Hong Kong-based investment group Integrated Whale Media Investments since 2014.

See Alirocumab and Forbes

Health Canada

Health Canada (HC; Santé Canada, SC)Health Canada is the applied title under the Federal Identity Program; the legal title is Department of Health.

See Alirocumab and Health Canada

Hypercholesterolemia

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood.

See Alirocumab and Hypercholesterolemia

Immunoglobulin heavy chain

The immunoglobulin heavy chain (IgH) is the large polypeptide subunit of an antibody (immunoglobulin).

See Alirocumab and Immunoglobulin heavy chain

Immunoglobulin light chain

The immunoglobulin light chain is the small polypeptide subunit of an antibody (immunoglobulin).

See Alirocumab and Immunoglobulin light chain

Indication (medicine)

In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery.

See Alirocumab and Indication (medicine)

Industrial fermentation

Industrial fermentation is the intentional use of fermentation in manufacturing processes.

See Alirocumab and Industrial fermentation

Injection site reaction

Injection site reactions (ISRs) are reactions that occur at the site of injection of a drug.

See Alirocumab and Injection site reaction

Injunction

An injunction is an equitable remedy in the form of a special court order that compels a party to do or refrain from specific acts.

See Alirocumab and Injunction

International nonproprietary name

An international nonproprietary name (INN) is an official generic and nonproprietary name given to a pharmaceutical drug or an active ingredient.

See Alirocumab and International nonproprietary name

Investigational New Drug

The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved.

See Alirocumab and Investigational New Drug

Kidney dialysis

Kidney dialysis (from Greek,, 'dissolution'; from,, 'through', and,, 'loosening or splitting') is the process of removing excess water, solutes, and toxins from the blood in people whose kidneys can no longer perform these functions naturally.

See Alirocumab and Kidney dialysis

LDL receptor

The low-density lipoprotein receptor (LDL-R) is a mosaic protein of 839 amino acids (after removal of 21-amino acid signal peptide) that mediates the endocytosis of cholesterol-rich low-density lipoprotein (LDL).

See Alirocumab and LDL receptor

Low-density lipoprotein

Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water.

See Alirocumab and Low-density lipoprotein

Medication

A medication (also called medicament, medicine, pharmaceutical drug, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease.

See Alirocumab and Medication

Monoclonal antibody

A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell lineage made by cloning a unique white blood cell. Alirocumab and monoclonal antibody are monoclonal antibodies.

See Alirocumab and Monoclonal antibody

Patent infringement under United States law

In the United States, a valid patent provides its proprietor with the right to exclude others from practicing the invention claimed in that patent.

See Alirocumab and Patent infringement under United States law

PCSK9

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene in humans on chromosome 1.

See Alirocumab and PCSK9

Pharmacy benefit management

In the United States, a pharmacy benefit manager (PBM) is a third-party administrator of prescription drug programs for commercial health plans, self-insured employer plans, Medicare Part D plans, the Federal Employees Health Benefits Program, and state government employee plans.

See Alirocumab and Pharmacy benefit management

Placebo

A placebo is a substance or treatment which is designed to have no therapeutic value.

See Alirocumab and Placebo

Priority review

Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease.

See Alirocumab and Priority review

Proteolysis

Proteolysis is the breakdown of proteins into smaller polypeptides or amino acids.

See Alirocumab and Proteolysis

Recombinant DNA

Recombinant DNA (rDNA) molecules are DNA molecules formed by laboratory methods of genetic recombination (such as molecular cloning) that bring together genetic material from multiple sources, creating sequences that would not otherwise be found in the genome.

See Alirocumab and Recombinant DNA

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.

See Alirocumab and Regeneron Pharmaceuticals

Sanofi

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France.

See Alirocumab and Sanofi

Statin

Statins (or HMG-CoA reductase inhibitors) are a class of medications that reduce illness and mortality in people who are at high risk of cardiovascular disease.

See Alirocumab and Statin

Subcutaneous administration

Subcutaneous administration is the insertion of medications beneath the skin either by injection or infusion.

See Alirocumab and Subcutaneous administration

The New England Journal of Medicine

The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society.

See Alirocumab and The New England Journal of Medicine

Therapy

A therapy or medical treatment is the attempted remediation of a health problem, usually following a medical diagnosis.

See Alirocumab and Therapy

See also

PCSK9 inhibitors

References

[1] https://en.wikipedia.org/wiki/Alirocumab

Also known as C6472H9996N1736O2032S42, Praluent, REGN727, SAR236553.